Brief: Dilafor Signs Term Sheet With Exeltis For License Deal
Jan 21 (Reuters) - Karolinska Development AB KDEV.ST: KAROLINSKA DEVELOPMENT’S PORTFOLIO COMPANY DILAFOR SIGNS BINDING TERM SHEET WITH EXELTIS FOR A LICENSE AGREEMENT REGARDING TAFOXIPARIN DILAFOR TO RECEIVE SALES-BASED MILESTONES AND ROYALTIES Source text: ID:nGNEbT27Np Further company coverage: KDEV.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Kdventures AB
See all newsRefile: BRIEF-Umecrine Cognition Gets Notice Of Allowance In US
Brief: KDventures' Modus Therapeutics Pauses Enrollment In Phase 2A Study
Brief: KDventures' AnaCardio Raises €62.5 Million
Brief: Kdventures' Umecrine Cognition Gets Two USPTO Notices Of Allowance For Patent Applications
Brief: Kdventures' Modus Therapeutics Carries Out Directed Issue